Mission: To accelerate breakthroughs by providing today's best young scientists with funding to pursue innovative cancer research. The foundation's goals are to identify and fund the best and brightest early-career scientists in cancer research; enable them to take risks on bold new ideas; and accelerate the translation of scientific discoveries into new ways to prevent or cure all forms of cancer. Its internationally recognized and highly competitive grant programs are designed to achieve these goals.
Results: Since 1946, Damon Runyon scientists, including 11 Nobel Laureates, have made some of the most important discoveries in cancer research, including: > Groundbreaking research confirming the link between cigarette smoking and lung cancer (1954) > Identification of the first cancer-causing gene (1970) > Development of treatments to arm the immune system against cancer cells (2008) A timeline of milestones and achievements is also available on www.damonrunyon.org.
Direct beneficiaries per year: All Damon Runyon awardees receive support for at least three years. Each year, the Foundation supports the work of approximately 40 new, exceptional researchers in addition to those already receiving funds. In its history, Damon Runyon has enabled more than 3,250 scientists to conduct the most innovative cancer research.
Programs: Fellowship awards: supports the training of the brightest postdoctoral scientists as they embark upon their research careers. This funding enables them to be trained by established investigators in leading research laboratories across the country, while independently conducting leading-edge science that will bring new understanding and cures for cancer.
clinical investigator awards: supports early career physician-scientists conducting patient-oriented research. The goal of this program is to increase the number of physicians capable of moving seamlessly between the laboratory and the patient's bedside in search of breakthrough treatments.
rachleff innovation awards: supports the next generation of exceptionally creative thinkers with "high risk/high reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer, but lack sufficient preliminary data to obtain traditional funding.